MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1

Molecular Cancer Research

Volumn 9, Issue 3, 2011, Pages 320-331

  Huang, Ying ^a   Rachid, Zakaria ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; SHORT HAIRPIN RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZRS 1;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SENSITIZATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DACARBAZINE; DIAZONIUM COMPOUNDS; DNA METHYLATION; ENZYME INHIBITORS; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952842273     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0407     Document Type: Article

References (38)

1. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 2008;8:417-34. (Pubitemid 351962088)
2. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45. (Pubitemid 47325607)
3. Sartore-Bianchi A, Cerea G, Schiavetto I, Giannetta L, Ricotta R, Maugeri MR, et al. Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. Ann Oncol 2006;17:ii49-51.
4. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28:S32-7.
5. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28:S24-31.
6. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-10. (Pubitemid 351654331)
7. Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther 2004;311:1163-70. (Pubitemid 39612724)
8. Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP, et al. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res 2007;13:331-40. (Pubitemid 46121887)
9. Katsoulas A, Rachid Z, McNamee JP, Williams C, Jean-Claude BJ. Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Mol Cancer Ther 2008;7:1033-43.
10. Cavazzoni A, Alfieri RR, Carmi C, Zuliani V, Galetti M, Fumarola C, et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther 2008;7:361-70. (Pubitemid 351302529)
11. Rachid Z, Macphee M, Williams C, Todorova M, Jean-Claude BJ. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg Med Chem Lett 2009;19:5505-09.
12. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007;56:275-87. (Pubitemid 47488901)
13. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A 1999;96:10764-9. (Pubitemid 29442218)
14. Kohn KW, Erickson LC, Ewig RAG, Friedman CA. Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 1976;15:4629-37.
15. Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nature Protocols 2006;1:23-9.
16. Sabharwal A, Middleton MR. Exploiting the role of O6-methylguanine- DNA-methyltransferase (MGMT) in cancer therapy. Curr Opion Pharmacol 2006,6:355-63.
17. Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD. O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 2005;11:2747-55.
18. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
19. Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997;3:837-47.
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 1990;82:1107-12. (Pubitemid 20213250)
21. Scheid MP, Schubert KM, Duronio V. Regulation of bad phosphorylation and association with Bcl-xL by the MAPK/Erk Kinase. J Biol Chem 1999;274:31108-13.
22. Ohi N, Nishikawa Y, Tokairin T, Yamamoto Y, Doi Y, Omori Y, et al. Maintenance of bad phosphorylation prevents apoptosis of rat hepatic sinusoidal endothelial cells in vitro and in vivo. Am J Pathol 2006;168:1097-106.
23. Lacoste S, Castonguay A, Drouin R. Formamidopyrimidine adducts are detected using the comet assay in human cells treated with reactive metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Mut Res 2006;600:138-49.
24. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-26. (Pubitemid 28406819)
25. Cui Q, Yu Jh, Wu Jn, Tashiro Si, Onodera S, Minami M, et al. P53-mediated cell cycle arrest and apoptosis through a caspase-3-independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin 2007;28:1057-66. (Pubitemid 47020485)
26. Carrier F, Georgel PT, Pourquier P, Blake M, Kontny HU, Antinore MJ, et al. Gadd45, a p53-Responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol 1999;19:1673-85. (Pubitemid 29098226)
27. Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 2004;91:1066-73. (Pubitemid 39336244)
28. Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006;12:710-17. (Pubitemid 43259849)
29. Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008;99:375-82.
30. Mizuarai S, Yamanaka K, Kotani H. Mutant p53 Induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 2006;66:6319-26.
31. Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 2007;83:781-91.
32. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 2008;7:69-78.
33. Matheson SL. BFJ-CBJ: The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol 2004;67:1131-38.
34. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt Phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41. (Pubitemid 27456390)
35. Kaina B, Chrismann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2009;6:1079-99. (Pubitemid 47058389)
36. Flanagan SA, Robinson BW, Krokosky CM, Shewach DS. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Mol Cancer Ther 2007;6:1858-68. (Pubitemid 46954063)
37. Zienolddiny S, Ryberg D, Gazdar AF, Haugen A. DNA mismatch binding in human lung tumor cell lines. Lung Cancer 1999;47:15-25. (Pubitemid 29469712)
38. McNamee JP, McLean JR, Ferrarotto CL, Bellier PV. Comet assay: rapid processing of multiple samples. Mutat Res 2000;466:63-69. (Pubitemid 30177140)